Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
79.71
-2.25 (-2.75%)
Mar 3, 2026, 1:35 PM EST - Market open
Ionis Pharmaceuticals Revenue
In the year 2025, Ionis Pharmaceuticals had annual revenue of $943.71M with 33.83% growth. Ionis Pharmaceuticals had revenue of $203.33M in the quarter ending December 31, 2025, a decrease of -10.26%.
Revenue (ttm)
$943.71M
Revenue Growth
+33.83%
P/S Ratio
13.84
Revenue / Employee
$882,798
Employees
1,402
Market Cap
13.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 943.71M | 238.57M | 33.83% |
| Dec 31, 2024 | 705.14M | -82.51M | -10.48% |
| Dec 31, 2023 | 787.65M | 200.28M | 34.10% |
| Dec 31, 2022 | 587.37M | -223.09M | -27.53% |
| Dec 31, 2021 | 810.46M | 81.19M | 11.13% |
| Dec 31, 2020 | 729.26M | -393.34M | -35.04% |
| Dec 31, 2019 | 1.12B | 522.93M | 87.20% |
| Dec 31, 2018 | 599.67M | 85.50M | 16.63% |
| Dec 31, 2017 | 514.18M | 141.40M | 37.93% |
| Dec 31, 2016 | 372.78M | 89.07M | 31.40% |
| Dec 31, 2015 | 283.70M | 69.54M | 32.47% |
| Dec 31, 2014 | 214.16M | 66.88M | 45.41% |
| Dec 31, 2013 | 147.29M | 45.24M | 44.33% |
| Dec 31, 2012 | 102.05M | 2.96M | 2.99% |
| Dec 31, 2011 | 99.09M | -9.39M | -8.65% |
| Dec 31, 2010 | 108.47M | -13.13M | -10.80% |
| Dec 31, 2009 | 121.60M | 14.41M | 13.44% |
| Dec 31, 2008 | 107.19M | 48.85M | 83.72% |
| Dec 31, 2007 | 58.34M | 43.49M | 292.65% |
| Dec 31, 2006 | 14.86M | -13.48M | -47.57% |
| Dec 31, 2005 | 28.34M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jazz Pharmaceuticals | 4.27B |
| Genmab | 3.72B |
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Ascendis Pharma | 845.52M |
| BridgeBio Pharma | 502.08M |
IONS News
- 1 day ago - Ionis Pharmaceuticals, Inc. (IONS) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha
- 4 days ago - Ionis to present new data supporting DAWNZERA™ (donidalorsen) in hereditary angioedema at 2026 AAAAI Annual Meeting - Business Wire
- 4 days ago - Ionis Pharmaceuticals: Digesting Recent Events - Seeking Alpha
- 4 days ago - Ionis Pharmaceuticals, Inc. (IONS) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript - Seeking Alpha
- 5 days ago - Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG) - Business Wire
- 6 days ago - Ionis Pharmaceuticals, Inc. (IONS) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Ionis Guides Below 2026 Sales Views Despite Strong Growth From Lead Drug - Benzinga
- 6 days ago - Ionis reports fourth quarter and full year 2025 financial results and highlights progress on key programs - Business Wire